Skip to content
No picture yet

Revolade 25 mg – DIN 02361825

Revolade is Eltrombopag Olamine 25 mg (tablet), sold in Canada. It is used for aplastic anemia and idiopathic thrombocytopenic purpura. It is supplied by Novartis Pharmaceuticals Canada Inc. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.

Sold in Canada

Eltrombopag Olamine 25 mg

Brand
Revolade
Strength
25 mg
Used for
Aplastic anemia and idiopathic thrombocytopenic purpura
Form
Tablet
Manufacturer
Novartis Pharmaceuticals Canada Inc
Drug class
Thrombopoietin receptor agonist
Sold in
Canada
DIN
02361825

Source: Health Canada's Drug Product Database. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Eltrombopag Olamine pills and guides

What is Eltrombopag Olamine used for?

Eltrombopag Olamine is used for aplastic anemia and idiopathic thrombocytopenic purpura.

Medicine type
Thrombopoietin receptor agonist
Official uses from the US prescribing label

Treatment of Thrombocytopenia in Patients With Persistent or Chronic Immune Thrombocytopenia

Eltrombopag tablets are indicated for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding.

Treatment of Thrombocytopenia in Patients With Hepatitis C Infection

Eltrombopag tablets are indicated for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy.

Treatment of Severe Aplastic Anemia

  • Eltrombopag tablets are indicated in combination with standard immunosuppressive therapy (IST) for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.
  • Eltrombopag tablets are indicated for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.

Limitations of Use

  • Eltrombopag tablets are not indicated for the treatment of patients with myelodysplastic syndromes (MDS).
  • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection.

From the FDA-approved label on DailyMed (published Sep 14, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your medicine? Check the box

  • The box or bottle shows DIN 02361825.
  • It names Revolade, Eltrombopag Olamine 25 mg.
  • A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.

Sold in Canada as Revolade film-coated by Novartis Pharmaceuticals Canada Inc.

In Canada: prescription only.

Ingredients

Active: Eltrombopag (Eltrombopag Olamine)

Other Eltrombopag Olamine pills